Medical device and MedTech insights, news, tips and more

Echosens Launches FibroScan GO, Affordable State-of-the-Art, Non-Invasive Solution for Identifying Patients with Advanced Chronic Liver Disease

March 7, 2022


Echosens, a high-technology company offering the FibroScan® portfolio of solutions, is pleased to announce the launch of FibroScan GO, an affordable, cost-effective tool for screening liver health, improving liver health management at the point of care for primary care practices and reducing the flow of patients in secondary care centers. FibroScan GO is a solution for quickly and easily assessing liver stiffness using LSM by VCTE™ and CAP™ for liver fibrosis and steatosis assessment and management among patients with, or suspected of having, liver fibrosis and cirrhosis.

“Primary care practices can now manage and monitor at-risk patients and make an early diagnosis, which is essential for halting or reversing liver disease,” Dominique Legros, Group CEO, Echosens. “FibroScan GO is a powerful tool for the prognosis of disease course, enabling immediate medical decisions for improved patient outcomes and higher healthcare efficiency.”

Chronic liver disease is a public health crisis that affects 1.9 billion people worldwide and counts for two million deaths per year. The main causes of chronic liver disease include nonalcoholic fatty liver disease (NAFLD) and its more severe form nonalcoholic steatohepatitis (NASH), alcohol and viral hepatitis.

FibroScan GO enables operators to screen at-risk patients for early intervention and diagnosis, patient stratification and monitoring of disease progression. Key features include:

  • Integrates instantly into an office-based practice with small footprint and connectivity
  • A smaller, mobile equipment for easy integration outside of secondary care
  • Enhanced clinical decision support with the Interpretation Guide and Scores by Echosens
  • Available on myFibroScan app
  • Centralized and secure data management with Echosens Cloud

This gold standard non-invasive solution is supported by 3000+ peer reviewed publications and 140+ guidelines. The fast, simple and non-invasive examination can be performed by any trained operator, including healthcare practitioner or nurse. The test is repeatable and reproducible and offers consistent results.

Legros adds, “Echosens is bringing greater peace of mind with FibroScan GO’s proactive and dedicated support team who assist with onsite installation and training. With a flexible and affordable pay per exam offer, this tool not only reduces referrals to secondary care, but also obviates the need for capital investment to achieve an early liver disease diagnosis that reduces the cost of liver-related illness.”

About Echosens

Pioneer in its field, Echosens significantly changed the practice of liver assessment with FibroScan®, the non-invasive solution for comprehensive management of liver health. FibroScan® is recognized worldwide and validated by over 3,000 peer reviewed publications and 140 international guidelines. Echosens has made FibroScan® available in over 100+ countries enabling millions of liver examinations worldwide.

See Full Press Release at the Source: Echosens Launches FibroScan GO, Affordable State-of-the-Art, Non-Invasive Solution for Identifying Patients with Advanced Chronic Liver Disease

Press Release by: Echosens

Legacy MedSearch has more than 30 years of combined experience recruiting in the medical device industry. We pride ourselves on our professionalism and ability to communicate quickly and honestly with all parties in the hiring process. Our clients include both blue-chip companies and innovative startups within the MedTech space. Over the past 10 years, we have built one of the strongest networks of device professionals ranging from sales, marketing, research & , quality & regulatory, project management, field service, and clinical affairs.

We offer a variety of different solutions for hiring managers depending on the scope and scale of each individual search. We craft a personalized solution for each client and position with a focus on attracting the best possible talent in the shortest possible time frame.

Are you hiring?
Contact us to discuss partnering with Legacy MedSearch on your position.

More insights

March 7, 2024
FDA Clears Dexcom’s First Over-the-Counter Continuous Glucose Monitor
Learn More
March 1, 2024
FDA greenlights Boston Scientific’s Novel Drug-Coated Balloon for Coronary In-Stent Restenosis
Learn More
February 21, 2024
Sparrow BioAcoustics Launches Software That Turns a Smartphone into a Stethoscope 
Learn More

Begin your legacy now. We are your medtech and medical device talent advisory firm.